https://scholars.lib.ntu.edu.tw/handle/123456789/452204
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | RUEY-LONG HONG | en_US |
dc.contributor.author | Tseng Y.-L. | en_US |
dc.contributor.author | FU-HSIUNG CHANG | en_US |
dc.creator | Hong R.-L.;Tseng Y.-L.;Fu-Hsiung Chang | - |
dc.date.accessioned | 2020-01-21T06:06:02Z | - |
dc.date.available | 2020-01-21T06:06:02Z | - |
dc.date.issued | 2000 | - |
dc.identifier.issn | 09237534 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034001881&doi=10.1023%2fA%3a1008394125040&partnerID=40&md5=d67db53a21e8e0f19d7baeb1dfc8bcf1 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/452204 | - |
dc.description.abstract | Background: There is lack of effective and safe chemotherapy for advanced hepatocellular carcinoma. Polyethylene glycol-coated (pegylated) liposomal doxorubicin (PLD) has long circulation time and enhanced drug accumulation in the tumor tissues. It has significant activity in Kaposi's sarcoma, breast and ovarian cancers and the acute adverse effects of free drug are reduced. Patients and methods: A patient with advanced hepatocellular carcinoma was treated with PLD and a pharmacokinetic study was performed. Initial serum total and direct bilirubin were 3.6 and 6.8 folds of upper normal, respectively, and an indocyanine green clearance test at 15 minutes was 26.3% (normal < 15%). Results: Compared to cases with normal liver function, increased volume of distribution of doxorubicin correlated with a large amount of ascites (P < 0.05). The clearance of drug was unexpectedly higher than in cases with normal liver function (P < 0.05). According to the pharmacokinetic studies, the disposition of PLD in this case has not been retarded even in the presence of severe liver dysfunction. Only minimal toxicities including grade 2 stomatitis and moderate leukopenia were observed. The tumor had a partial remission and the patient survived nine months after PLD treatment. Conclusion: PLD could serve as a safe and effective treatment for hepatocellular carcinoma even in the presence of impaired liver function. Its role in treating advanced hepatocellular carcinoma is worthy of further study. | - |
dc.relation.ispartof | Annals of Oncology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | doxorubicin; liposome; macrogol; adult; advanced cancer; area under the curve; article; cancer chemotherapy; cancer mortality; case report; disease severity; drug accumulation; drug distribution; drug effect; drug safety; human; liver cell carcinoma; liver function; male; priority journal; Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Drug Carriers; Fatal Outcome; Humans; Liposomes; Liver Neoplasms; Male | - |
dc.title | Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1023/A:1008394125040 | - |
dc.identifier.scopus | 2-s2.0-0034001881 | - |
dc.relation.pages | 349-353 | - |
dc.relation.journalvolume | 11 | - |
dc.relation.journalissue | 3 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Center for Biotechnology | - |
crisitem.author.dept | Biochemistry and Molecular Biology | - |
crisitem.author.orcid | 0000-0001-8100-7914 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | Others: University-Level Research Centers | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 生物化學暨分子生物學科研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。